Role of R-type calcium channels in the response of the perfused arterial and venous mesenteric vasculature of the rat to platelet-activating factor.
1. The vasoactive properties of platelet-activating factor (PAF) were studied in the arterial and venous vasculature of the rat double-perfused mesenteric bed. Although PAF (0.01-0.3 pmol) induced a dose-dependent vasodilatation of the arterial mesenteric vasculature, it triggered only vasoconstrictions on the venous side, with an intact endothelium as bradykinin induced a significant venodilatation. 2. NG-nitro-L-arginine methyl ester (L-NAME, 100 microM), a nitric oxide synthase inhibitor, markedly reduced the vasodilatation induced by PAF in the arterial mesenteric vasculature and potentiated the contractile responses of the venous side to the same agent. 3. The PAF antagonist, WEB-2170, markedly reduced the response to PAF on both sides of the mesenteric vasculature. However, the IC50 of WEB-2170 against PAF was reached at a much higher concentration (1 x 10(-8) M) on the arterial side than on the venous side (5.3 x 10(-11) M). Furthermore, a second antagonist of PAF receptors, SRI-63441, although being less potent on the venous vasculature than WEB-2170, was equipotent in antagonizing the venoconstriction and the arterial dilatation induced by PAF (IC50 of SRI-63441, arterial side: 2.9 x 10(-9) M; venous side: 3.1 x 10(-9) M). 4. The dual L- and R-calcium channel blocker, isradipine (PN 200-110), but not the L-type calcium channel blocker, nifedipine, markedly reduced the PAF-induced vasoactive properties on both sides of the mesenteric vasculature. 5. Our results illustrate the differential vasoactive properties of PAF in the mesenteric vasculature of the rat. These vasoactive responses occur following activation of specific receptors for PAF or,alternatively, through activation of R-type calcium channels.
Claing
A
A
Department of Pharmacology, Faculty of Medicine, Université de Sherbrooke, Québec, Canada.
Bkaily
G
G
Berthiaume
N
N
Sirois
P
P
Rola-Pleszczynski
M
M
D'Orléans-Juste
P
P
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D015220:Calcium Channels / Q000502:physiology*; D017275:Isradipine / Q000494:pharmacology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects* / Q000502:physiology; D008642:Mesenteric Veins / Q000187:drug effects* / Q000502:physiology; D019331:NG-Nitroarginine Methyl Ester; D010477:Perfusion; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011806:Quinolinium Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014230:Triazoles / Q000494:pharmacology
D001381:Azepines; D015220:Calcium Channels; D010972:Platelet Activating Factor; D011806:Quinolinium Compounds; D014230:Triazoles; C050531:SRI 63-441; D001120:Arginine; C063964:bepafant; D019331:NG-Nitroarginine Methyl Ester; D017275:Isradipine